PFIZER INC (PFE)
US7170811035 - Common Stock
Billionaires Are Buying These High-Yield Dividend Stocks Left and Right. Should You Follow Their Lead?
Billionaire money managers have bought millions of shares of both Pfizer and Walgreens Boots Alliance this year.
Billionaires Are Buying These High-Yield Dividend Stocks Left and Right. Should You Follow Their Lead?
Billionaire money managers have bought millions of shares of both Pfizer and Walgreens Boots Alliance this year.
These S&P500 stocks are the most active in today's session
Stay informed about the most active S&P500 stocks in today's session as we take a closer look at what's happening on the US markets on Friday. Discover the stocks that are generating the highest trading volume and driving market activity.
Pfizer Inc. (PFE) Is a Trending Stock: Facts to Know Before Betting on It
Pfizer (PFE) has been one of the stocks most watched by Zacks.com users lately. So, it is worth exploring what lies ahead for the stock.
7 Value Stocks to Buy and Hold for a Decade of Dominance
Discover the enduring value of seven key value stocks to buy and hold in diverse sectors, presenting unparalleled opportunities.
Could Novavax Become the Next Moderna?
Sanofi believes in Novavax's vaccine strengths...
2 Top Growth Stocks Down 24% and 50% to Buy With $100
Investors might be remiss to overlook these stocks.
7 Pharma Stocks Harnessing AI Brainpower for Big Breakthroughs
AI continues to impact pharma stocks to buy in a major way, with these shares particularly well positioned as things heat up.
Patent Peril: 3 Stocks at Risk From the FTC’s Drug Crusade
The FTC is putting these three drug stocks at risk by trying to strip their therapies of protection from generics.
Pfizer offers up to $250 million to settle Zantac cancer lawsuits, FT reports
The drugmaker was set to pay between $200 million and $250 million in the settlement, the newspaper reported, citing two people briefed on the deal. The settlement was disclosed in a court filing in Delaware last week, and is aimed at reducing Pfizer's potential liability, the report added. Pfizer did not immediately reply to Reuters' request for comment.
Which S&P500 stocks are the most active on Wednesday?
Which S&P500 stocks are the most active on Wednesday?
7 Cheap Value Stocks to Buy Now: May 2024
Worried about a potential market correction? These seven cheap value stocks are bargains today regardless of the broader economic climate.
3 No-Brainer Stocks to Buy With $500 Right Now
A modest amount of money can go a long way on Wall Street when it's put to work in game-changing companies.
2 Healthcare Stocks to Buy and Hold for Great Long-Term Potential
These healthcare stocks offer completely different approaches to long-term investment gains.
Generis Welcomes Max Kelleher as New Chief Executive Officer
LONDON - May 14, 2024 - PRLog -- Generis, creator of the cloud data, content, and business process management platform CARA™, today announced that Max Kelleher will be stepping into the role of Chief Executive Officer, following 5 years as COO of Generis. James Kelleher, the previous CEO will now work as President. This change also means a new leadership structure with Rex Harrison stepping to the COO role, and Mark Diaper becoming CIO. Mariusz Pala will continue to lead the product development in the CTO position.Max's top priorities as CEO are to drive operational excellence, foster continued innovation, and expand market reach across new industries, all while ensuring Generis maintains the culture and core values which are integral to the company.Speaking of his new position Max stated: "We're at a thrilling moment in our transition from a small organisation with a visionary leader, to an absolute rocket ship, as we spread both our incredible product and our working culture. With >400% growth as a business, we need more hands on deck than ever, ensuring this product and culture we've built is supported from the bottom up. We've put together a brilliant, experienced leadership team with James, Rex, Mark, Mariusz, and me to take Generis into this new, exciting era."Generis's flagship product the CARA Platform removes the technological and financial drawbacks of a network of individual systems. Users can consolidate their complex regulated business processes, data and content on a single platform. Information can be created, located and re-used instantly - in any process across the organisation - leading to accelerated work, supported by more accurate information. One of Max's key initiatives in his new responsibilities is to ensure Generis maintains its technical lead with the CARA Platform, further improving quality in everything they do to continue providing speed, flexibility, and customer satisfaction."Generis has always been a collection of the warmest, brightest, and most brilliant people in the industry – that's our not-so-simple secret to success." Added Max. "The CARA Life Sciences Platform is already playing a huge role in changing how the companies in Life Sciences not only go about their work but also how they fundamentally structure their companies. The CARA Core Platform has very few limits, it is this flexibility which will elevate it to a well-recognised status in Aerospace, Automotive, Banking, Construction, Engineering and Financial Services in the coming years."About GenerisGeneris is a UK-headquartered provider of world-class data, content and business process management for regulated industries globally of over 20 years. With the formalisation of the CARA Life Sciences Platform, and a new generation of customers and partners leveraging the CARA Enterprise Cloud Platform as a low-code enterprise platform for multiple verticals and use cases ranging from Life Sciences to Financial Services, Government, Insurance and others, servicing clients including Pfizer, Bayer, Merck, VISA, Screen Actors Guild, Fannie Mae, City of Sacramento and many others. More at generiscorp.com.
Is This a Setback for Moderna?
Moderna's shares slipped after the company announced the delay.
Curious about the most active S&P500 stocks in today's session? Get insights into the stocks that are leading the way in terms of trading volume and market attention.
Most active S&P500 stocks in Monday's session
One stock is dragging down the S&P 500's earnings growth
S&P 500 companies have had a solid Q1 earnings season, with one key exception: drugmaker Bristol Myers Squibb.
Microsoft, Amazon, Pfizer, and others are investing a record $16 billion in France
The companies announced the investments as part of France's seventh annual Choose France Summit
How Viking Therapeutics Stock Could 30x
This mid-cap biopharma may one day be a titan of the industry.
Astellas Showcases Scientific Advancements Across its Oncology Portfolio at 2024 ASCO Annual Meeting
/PRNewswire/ -- Astellas Pharma Inc. (TSE: 4503, President and CEO: Naoki Okamura, "Astellas") will share new research from across its innovative portfolio of...
The Zacks Analyst Blog Highlights Amazon, Visa, Pfizer, Martin Marietta Materials and Zimmer Biomet
Amazon, Visa, Pfizer, Martin Marietta Materials and Zimmer Biomet are included in this Analyst Blog.
Pfizer’s next move: Can it break above $30?
Pfizer Inc. (NYSE:PFE) faced a challenging 2023 in the stock market, with its shares plummeting from over $50 to a low of $25. However, recent developments suggest a potential turnaround for the pharmaceutical giant. On May 1, 2024, Pfizer reported better-than-expected results for the first quarter of the year. Their non-GAAP earnings per share of […]
Want $1,000 in Dividend Income? Here's How Much You'd Have to Invest in Pfizer Stock
Pfizer stock currently has a 5.9% dividend yield, making it an attractive target for income investors.
Pfizer and AstraZeneca announce new investments of nearly $1 billion in France
President Emmanuel Macron will kick off the annual 'Choose France' event aimed at wooing big overseas businesses and investors on Monday.
Earn $1000 Every Month From These 3 Stocks
All 3 companies pay growing dividends.
Stay informed about the most active stocks in the S&P500 index on Friday's session. Discover the stocks that are generating the highest trading volume and driving market activity.
Explore the S&P500 index on Friday and find out which stocks are the most active in today's session. Stay updated with the stocks that are capturing market interest.
What's going on in today's session: S&P500 most active stocks
Thursday's session: most active stock in the S&P500 index
Most active S&P500 stocks in Wednesday's session
Which S&P500 stocks are the most active on Wednesday?
These S&P500 stocks are the most active in today's session
Stay informed about the most active stocks in the S&P500 index on Tuesday's session. Discover the stocks that are generating the highest trading volume and driving market activity.
Which S&P500 stocks are the most active on Monday?
Activity analysis of S&P500 on 2024-05-06: most active stocks in today's session.
What's going on in today's session: S&P500 most active stocks
Stay informed about the most active stocks in the S&P500 index on Thursday's session. Discover the stocks that are generating the highest trading volume and driving market activity.
Thursday's session is buzzing with activity. Check out the stocks that are attracting the most attention and driving market activity!
Let's dive into the action on the US markets on Thursday. Here are the most active stocks that are driving the market today.
Uncover the latest developments among S&P500 stocks in today's session. Stay tuned to the S&P500 index's top gainers and losers on Wednesday.
Curious about the S&P500 stocks that are in motion on Wednesday? Join us as we explore the top movers within the S&P500 index during today's session.
Curious about the most active S&P500 stocks in today's session? Get insights into the stocks that are leading the way in terms of trading volume and market attention.
Stay informed about the most active stocks in the S&P500 index on Wednesday's session. Discover the stocks that are generating the highest trading volume and driving market activity.
Top S&P500 movers in Wednesday's session
Stay informed about the performance of the S&P500 index in the middle of the day on Wednesday. Uncover the top gainers and losers in today's session for valuable insights.
Explore the S&P500 index on Tuesday and find out which stocks are the most active in today's session. Stay updated with the stocks that are capturing market interest.
Let's have a look at the most active S&P500 stocks in today's session.